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plexity with new agents and lack of pediatric data highlights a need
for collaboration between HSCT units.551
RETROSPECTIVE ANALYSIS OFWEEKLY INTRAVENOUS IMMUNOGLOBU-
LIN PROPHYLAXIS VERSUS INTRAVENOUS IMMUNOGLOBULIN BY IGG
LEVEL MONITORING IN HEMATOPOIETIC STEM CELL TRANSPLANT RE-
CIPIENTS
Howell, J.E.1, Gulbis, A.M.1, Qazilbash,M.H.2 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2The University of Texas
MD Anderson Cancer Center, Houston, TX
Background: Patients undergoing hematopoietic stem cell trans-
plant (HSCT) may have a higher incidence of infections due to sec-
ondary hypogammaglobulinemia. A recent meta-analysis evaluated
intravenous immune globulin (IVIG) in a prophylactic setting and
concluded routine use had no benefit in survival or infection preven-
tion inHSCT.The study suggestedmonitoring of IgG levels and re-
placing with IVIG in high risk patients.
Methods: All allogeneic HSCT patients who received prophylactic
IVIG 0.2 gm/kg IV onceweekly (n5 115) from admission to day +90
were compared to patients who received IVIG based on low IgG
levels (n5 114) between 1/09 and 8/09. The IgG levels were drawn
upon admission, day +30, day +60, and day +90. Utilization of IVIG,
incidence of veno-occulsive disease (VOD), graft versus host disease
(GVHD), and documented infections were recorded during the first
100 days after transplant.
Results:The weekly control group (n 5 115) had a median age of
49 compared to 54 years in the IVIG by level group (n 5 114).
No significant difference in type of transplant, except a higher
number of matched un-related donors (MUD) in the by level
group (62 vs 41, p 5 0.01). There were no significant differences
in occurrence of GVHD (55 vs 50), VOD (2 vs 0), or in infections
such as RSV (3 vs 1), VZV (1 vs 0), HSV (3 vs 8), Adenovirus (2 vs
1), polyoma/BK virus (18 vs 26), bacterial infection (49 vs 38), or
fungal infection (12 vs 7) in weekly versus by IgG levels respec-
tively. A higher incidence of para-influenza occurred in the
weekly group (9 vs 0, p 5 0.003) correlating with flu season.
IVIG cost in the weekly control group totaled AWP $924,408
vs $252,547, with overall savings of $671,816 in the IVIG by level
group.
Conclusion:With no difference in major complications, rate of in-
fection, and a significant savings in IVIG use, a change in institu-
tional practice was implemented. IgG levels are now monitored
monthly and replacement is done based on low IgG level.552
RETROSPECTIVE ANALYSIS OF THE INCIDENCE OF SYMPTOMATIC VE-
NOUS THROMBOEMBOLISM AMONG PATIENTS WITH HEMATOLOGIC
MALIGNANCY
Hills, H., Broyles, J., Oliphant, C., Stelts, S. Methodist University Hospi-
tal, Memphis, TN
A growing body of evidence shows similar or increased venous
thromboembolism (VTE) risk in specific hematologic malignancies,
but few recommendations for VTE prophylaxis in hematologic ma-
lignancy exist. This study will investigate the incidence and trends of
VTE among hematologic malignancy patients to identify patients at
higher risk of VTE.
Methods: Clinical data was collected retrospectively from 200 ad-
missions to Methodist University Hospital from December 2008
to October 2009 with primary or secondary diagnoses of hemato-
logic malignancy. The primary objective is the incidence of symp-
tomatic VTE. Secondary objectives include rate of appropriate
VTE prophylaxis, risk of VTE in patients receiving VTE prophy-
laxis, subgroup analyses to determine populations at higher risk for
VTE, length of stay with occurrence of symptomatic VTE, inci-
dence of VTE surrounding implementation of hospital-wide VTE
prophylaxis protocol, and all-cause mortality versus possible VTE-
associated deaths.Results: A total of 144 patients were represented in 200 admis-
sions included in this study. The most common diagnoses
included were non-Hodgkin’s lymphoma (NHL, 24.3%), multi-
ple myeloma (MM, 24.3%), and acute myelocytic leukemia
(AML, 18.1%), and a majority of patients were African Ameri-
can. In April 2009, an automated screening tool for VTE pro-
phylaxis was implemented that both assesses VTE risk and
bleeding risk and offers three elective therapy options for
VTE prophylaxis. Admissions were stratified according to the
implementation date (100 before, 100 after protocol). Twelve
VTE events were observed across all 200 admissions (6%).
Nine VTE occurred prior to the protocol and 3 occurred after
the prophylaxis protocol, not statistically significant. NHL
(13%), chronic myelocytic leukemia (CML, 12.5%), and Hodg-
kin’s lymphoma (HL, 8.3%) had the highest rates of VTE. VTE
prophylaxis use increased by 160% after implementation of the
VTE prophylaxis protocol, (p 5 0.003). Use of VTE prophy-
laxis was not associated with any decreased risk of VTE or
length of stay.
Conclusion: Incidence of VTE among the local malignant hematol-
ogy patient population is similar to previously reported data, with
highest VTE rates found in those patients with NHL, CML, and
HL. The apparent lack of efficacy of VTE prophylaxis in this study
may reflect either inaccurate current definitions of adequate VTE
prophylaxis or the practice of holding anticoagulants in the setting
of thrombocytopenia.553
VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM SURVEILANCE AND
INFECTION IN AUTOLOGOUS AND ALLOGENEIC TRANSPLANTATION
Trifilio, S., Mehta, J. Northwestern Memorial Hospital
Introduction: Colonization with Vancomycin-resistant Enterococ-
cus Faecium(VRE) places patients at increased risk for VRE infec-
tion. Variable rates of colonization and infection have been
reported for hematapoeticc stem cell transplantion recipients.
Herein we reivew VRE colonization rates amongst 882 autologous
and allogeniec HSCT recipients and assess for risk factors associated
with the development of VRE infection.
Methods:Medical records for 822 consecutive HSCT recipient in-
patient admissions between 8/2004 to 8/2008were reviewed for data.
Pharmacy records were utilized to obtain data formedication. All pa-
tients were screened for VRE upon admission and weekly thereafter.
All patients received acyclovir, azole antifungals and ciprofloxacin as
prophylaxis. Positive VRE BAL cultures were excluded from infec-
tion analysis. Chi-square analysis was used for statistical analysis.
This study was approved by NMH IRB.
Results:For 822HSCT recipients reviewed (207 allogeneic and 615
autologous), new colonization developed in 136 patients (17%),
while 41 patients were VRE colonized prior to admission. Overall
28 patients (3.4%) developed VRE infection (urine 5 11, blood 5
17, multiple 5 3. No correlation was observed between age, sex,
or administration of a neutropenic diet and VRE colonization or in-
fection. Allogeneic transplant(p5 .013), especially melphalan based
RIST was associated with increased VRE infection (p 5 .011). Co-
infection wth Strept Viridans occurred more frequently in VRE in-
fected patients(p 5 .0001). Prior VRE colonization occurred in
15/28 patients (54%) who developed VRE infection compared to
13/651 who did not.(p 5 .0001). Median time to infection was
10days. A correlation between C.Diff infection and VRE coloniza-
tion was identified(p 5 .0014). Almost all patients received wide
spectrum B-Lactam antibiotics and vancomycin, which may explain
the lack of correlation between these antibiotics and the develop-
ment of VRE, however prior exposure to caspofungin was observed
more frequently in patients with VRE infection(p 5 .0001). All
treated patients received linezolid. Time to engraft was the same
for auto and all patients, with or without VRE. Crude in-patient
overall mortality was significantly higher in patients with VRE
infections (p 5 .0002).
Conclusion: VRE colonization and infection increase morbidity
and mortality post HSCT. Heightened awareness and correction
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infection.554
ALTERNATING REGIMEN HYPER CVAD + IMATINIB IN PH (+) ALL PA-
TIENT ON HIGH-FLUX DIALYSIS
Stelts, S.D.1, Butler, C.2, Goorha, S.2 1Methodist University Hospital,
Memphis, TN; 2University of Tennessee Cancer Institute, Memphis, TN
Lack of pharmacokinetic data on chemotherapy clearance in
high flux hemodialysis hinders safe and effective dosing. We pres-
ent a case of a 58 year old female diagnosed in September 2009
with Ph (+) ALL and a past medical history of focal segmental glo-
merular sclerosis on hemodialysis. The patient intially presented
with worsening renal function, fevers and peripheral blasts.
Upon diagnosis of Ph (+) ALL, the decision was made to treat
with Hyper CVAD, a regimen of hyper fractionated cyclophos-
phamide, doxorubicin, vincristine and dexamethasone (odd cycle)
alternating cycles with high dose methotrexate and high dose
cytarabine (even cycle). High flux hemodialysis is relatively new,
utilizing improved membranes that efficiently remove low molec-
ular weight solutes and that are more effective at removing
medium and high molecular weight solutes. Currently the dosing
recommendations for chemotherapy are based on low flux hemo-
dialysis. Weighing the potential for improved solute clearance and
manufacturer dosing recommendations, no dose adjustments were
made for the odd cycles of Hyper CVAD. Imatinib was started at
100 mg for cycle 1, titrated up to 200 mg by cycle 3 and increased
to 400 mg at completion without side effects. Methotrexate is
poorly removed by low flux hemodialysis and only one case report
in a single patient provides pharmacokinetic information on
removal by high flux hemodialysis. For even cycles of Hyper
CVAD the methotrexate was initially dosed at 200 mg/m2, deter-
mined by estimating a dose cleared by 1 high flux hemodialysis
session using the time averaged clearance reported in the case
report by Murashima and colleagues. The methotrexate was
adequately removed based on serum levels and patient tolerance.
The dosage was increased to 500 mg/m2 for subsequent cycles.
Further dose escalation was halted due to development of febrile
neutropenia requiring hospitalization. Cytarabine was dosed at
100 mg/m2 continuous infusion for cycle 1 and increased to 200
mg/m2 base on manufacturer recommendations. The patient tol-
erated 8 cycles of Hyper CVAD with minimal side effects and 2
admissions for neutropenic fever. Complete remission was docu-
mented in December 2009. She remained in remission for 4
months after completion in April 2009. Recently reinduced with
Hyper CVAD, peg asparaginase, and dasatinib with documented
molecular remission.555
DRUG-DRUG INTERACTION BETWEEN TACROLIMUS AND AZOLE ANTI-
FUNGAL AGENTS, ITRACONAZOLE AND VORICONAZOLE, IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
Udagawa, R.1, Koido, K.1, Watabe, D.1, Yokote, N.1, Kim, S.-W.2,
Mori, S.-I.2, Tanosaki, R.2, Heike, Y.2, Fukuda, T.2, Yamamoto, H.1
1National Cancer Center Hospital, Tokyo, Japan; 2National Cancer Cen-
ter Hospital, Tokyo, Japan
Background: The blood concentration of tacrolimus (TAC) is
known to be increased by concomitant administration of voricona-
zole (VRCZ) and itraconazole (ITCZ), azole anti-fungal agents.
We investigated changes in blood concentrations of TAC before
and after concomitant administration of VRCZ or ITCZ to exam-
ine the optimal timing for monitoring blood concentrations of
TAC.
Patients and Methods: We studied retrospectively patients who
underwent hematopoietic stem cell transplantation between April
2004 and June 2010 and started VRCZ or ITCZ use during TAC
administration. In a total of 34 patients receiving concomitant ad-
ministration of VRCZ (tablets, n 5 27; intravenous injection, n 5
7) and 11 receiving ITCZ (capsules [Cap], n 5 8; oral solution
[OS], n 5 3), the concentration/dose (C/D) ratio of TAC was ob-served from 10 days before through 35 days after the initiation of
VRCZ or ITCZ.
Results: In all VRCZ group patients, C/D ratios of TAC in-
creased after initiating VRCZ as compared with those before
(median, 293%; range, 131%-923%; P \ 0.001). Median time
to reach the peak C/D ratio was 8 days (range, 3-30 days).
When a loading dose was applied, the peak reached earlier (me-
dian, 6 days vs. 9.5 days; P 5 0.026). Then C/D ratios decreased
from peak (median, 50%; range, 23%-98%; P\ 0.001). In 10 pa-
tients in the ITCZ group, the C/D ratio increased after initiating
ITCZ as compared with those before (median, 267%; range,
141%-828%; P \ 0.001). Median time to reach the peak C/D
ratio was 19.5 days (range, 10-32 days). Patient who applied
a loading dose was none. The rates of C/D ratio increase differed
significantly between Cap and OS (median, 221% [range, 38%-
475%] vs. 513% [range, 440%-828%]; P 5 0.025) and times to
reach the peak C/D ratio were similar (median, 20 days vs. 19
days).
Conclusions: In the VRCZ group, since blood concentrations of
TAC transiently increased and then decreased, suggesting that care-
ful monitoring is required even after dose reduction. It is also sug-
gested that the optimal times for careful monitoring differ
depending on whether or not the loading dose is applied. In the
ITCZ group, the effects tended to appear after about 1 week. Signif-
icant increases in blood concentrations of TAC were observed in
patients who received ITCZ by OS.556
CORRELATION OF PATIENT CHARACTERISTICS INCLUDING AGE, OBE-
SITY, GENDER AND RACE ON THE METABOLISM OF BUSULFAN
Hutcherson, D.A.1, Mahoney, M.3, Ng, A.1, Wilson, N.M.1, Surati, M.1,
Shah, K.S.1, Flowers, C.R.2 1Emory Healthcare, Atlanta, GA; 2Emory
University School of Medicine, Atlanta, GA; 3University of Georgia,
Athens, GA
Background: Busulfan, in myeloablative doses, is commonly used in
conditioning regimens prior to hematopoietic stem cell transplanta-
tion (HSCT) and is associated with HSCT related toxicity including
hepatic veno-occlusive disease (VOD). Busulfan is predominantly
metabolized by conjugation with glutathione, both spontaneously
and by glutathione S-transferase catalysis. Busulfan dosing is com-
monly adjusted using therapeutic drug monitoring (TDM) to limit
toxicities. Whether patient characteristics such as race, age, obesity,
gender and prior chemotherapy can influence the metabolism of bu-
sulfan remains unclear.
Methods: A retrospective chart review was conducted in 302 pa-
tients receiving intravenous busulfan between April 26th, 2001 and
September 23rd, 2010. Data was obtained from an IRB approved bu-
sulfanTDMdatabase and included gender, race, age, weight, height,
BSA, BMI and elimination half-life obtained with the 1st dose of bu-
sulfan.
Results: Demographics included 172 males and 130 females, of
which there were 222 Caucasians, 50 African Americans and 30 pa-
tients of other races. The mean age was 43 with 113 patients
greater than 50 years old. Thirty patients weighed over 100 kg, 6
had a BMI \ 18.5, 175 had a BMI of 18.5 – 29.9 and 122 had
a BMI . / 5 30. The mean half-life for all patients was 188 min-
utes (ranging 108 to 640 minutes). For the 12 patients with a BSA
of 2.5 to 3.29, the mean half-life was 206 minutes (ranging 184 to
238 minutes). The half-lives for the small to large BMI groups were
186, 188 and 186 minutes. The half-life for females was 180 min-
utes vs. 194 minutes for males. The half-lives for Caucasians, Afri-
can Americans and other races were 187, 194 and 182 minutes,
respectively. Patients over 50 years old had a mean half-life of
189 minutes. For the entire group, wide variations in clearance
were observed with 11% of patients having a half-life . 230 and
8%\ 145 minutes. The maximum and minimum half-lives were
640 and 108 minutes.
Conclusion: Initial analysis of our data suggests that different dos-
ing strategies based on population specific parameters may not be
necessary. Pharmacists should continue to dose busulfan according
to their institutional guidelines but due to the wide variations
